FC
INDV icon

Foursixthree Capital’s Indivior Pharmaceuticals INDV Stock Holding History

Foursixthree Capital’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-373,231
Closed -$4.64M – 26
2024
Q4 		$4.64M Buy
+373,231
New +$3.84M 1.61% 11

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Foursixthree Capital's INDV Position: Q1 2025 in Review

Foursixthree Capital sold out of Indivior Pharmaceuticals (INDV) in Q1 2025, closing a stake of 373,231 shares — an estimated $4.64M sold.

Foursixthree Capital first reported a position in INDV in Q4 2024 and held it in 1 quarter. The position peaked at $4.64M in Q4 2024. 116 funds tracked by Wall St. Rank hold INDV as of Q1 2025.

  • Foursixthree Capital reported no remaining Indivior Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Foursixthree Capital sold 373,231 Indivior Pharmaceuticals shares in Q1 2025, an estimated $4.64M.
  • Foursixthree Capital first reported a position in Indivior Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Foursixthree Capital's Indivior Pharmaceuticals position peaked at $4.64M in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2025.

Based on Foursixthree Capital's 13F filing for Q1 2025, filed 15 May 2025.